drugset / Trial / NCT01466725
A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to assess if CC-930 is safe and tolerable in treating subjects with Discoid Lupus Erythematosus. Pharmacokinetic and pharmacodynamics will also be evaluated.
Timeline
- Start
- 2011-11-01
- Primary completion
- 2012-07-30
- Completion
- 2012-07-30
Outcome
Outcome not reported
Stopped: “The benefit/risk profile does not support continuation of this study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TANZISERTIB | Small molecule | 25 mg | — |
| Subject | TANZISERTIB | Small molecule | 50 mg | — |
| Subject | TANZISERTIB | Small molecule | 100 mg | — |